(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.
Bloomberg Intelligence
3,286 clip(s)
Intel Shares Fall on Report Nvidia Halts Production Test
Novo Nordisk Gets US Approval for Wegovy Obesity Pill
Larry Ellison’s Guarantee Ups Warner Bros. Stakes to a New Level